Carmustine

BreastfeedingPediatric
  • TRADE NAMES: Becenun; BiCNU (Bristol-Myers Squibb); Carmubris; Gliadel Wafer (Guilford); Nitrumon
  • INDICATIONS: Brain tumors, Hodgkin’s disease, multiple myeloma
  • CLASS: Alkylating agent, Nitrosourea
  • HALF-LIFE: initial: 1.4 minutes; secondary: 20 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin, Cimetidine, Clorazepate

PREGNANCY CATEGORY: D

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top